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Ohta, Takafumi, Naoyuki Hasebe, Shiro Tsuji, Kazuma Izawa,
Yin-Tie Jin, Shinsuke Kido, Syunsuke Natori, Motohiko Sato, and
Kenjiro Kikuchi. Unequal effects of renin-angiotensin system inhib-
itors in acute cardiac dysfunction induced by isoproterenol. Am J
Physiol Heart Circ Physiol 287: H2914–H2921, 2004. First published
August 5, 2004; doi:10.1152/ajpheart.00221.2004.—Several clinical
trials have demonstrated that angiotensin-converting enzyme inhibitor
(ACEI) and angiotensin II type 1 receptor blocker (ARB) are equally
effective in the treatment of chronic heart failure. However, this has
not been confirmed for acute cardiac dysfunction. We examined
whether ACEI or ARB prevents isoproterenol-induced acute left
ventricular (LV) dysfunction in dogs. LV dysfunction induced by a
large dose of isoproterenol (1 g kg1 min1, 3-h infusion) was
compared in dogs treated with ACEI (temocaprilat) or ARB (olme-
sartan). Atrial pacing induced a constant heart rate and use of
adjustable aortic banding provided a nearly constant afterload. LV
systolic function (LV dP/dt, fractional shortening, and ejection frac-
tion) and diastolic function ( and LV end-diastolic pressure) were
significantly deteriorated after isoproterenol infusion. The LV dys-
function was almost totally prevented by ARB but was only partially
prevented by ACEI. The partial effect of ACEI was complemented by
cotreatment with HOE-140, a bradykinin B2 receptor antagonist. At
baseline, the response to low doses of isoproterenol was significantly
attenuated by ACEI but not by ARB, and the ACEI-induced attenu-
ation was totally abolished by cotreatment with HOE-140. The re-
sponse to isoproterenol was significantly attenuated after 3 h of excess
isoproterenol loading, and it was almost completely preserved by
ARB but not by ACEI. In conclusion, acute LV dysfunction and
-adrenergic desensitization induced by excess isoproterenol admin-
istration were almost totally prevented by ARB but only partially
prevented by ACEI. These differences were attributable at least in part
to bradykinin pathways activated by ACEI administration in acute LV
dysfunction.
bradykinin; nitric oxide; catecholamine; oxidative stress
THE RENIN-ANGIOTENSIN SYSTEM (RAS) plays a crucial role in
chronic congestive heart failure. Angiotensin-converting en-
zyme inhibitor (ACEI) and angiotensin II (ANG II) type 1
(AT1) receptor blocker (ARB) improve the derangement of
hemodynamics and myocardial sympathetic activity (15, 31,
34, 35, 39) and prevent cardiovascular remodeling (24, 41) in
heart failure.
Apart from inhibition of the RAS, ACEI administration
enhances the bradykinin and nitric oxide (NO) pathways,
whereas ARB treatment stimulates ANG II type 2 (AT2)
receptors. These additional effects of ACEI and ARB appear to
make no essential differences in the consequences of treatment
of chronic heart failure; several clinical trials have demon-
strated that ACEI and ARB are equally effective in patients
with chronic heart failure (31, 34, 35). However, it is unknown
whether ACEI and ARB are equally effective in acute cardiac
dysfunction.
Three major clinical trials have demonstrated that ACEI is
effective in patients with acute myocardial infarction when it is
started 3–16 days after the onset (16) of the infarction. A recent
meta-analysis of four clinical trials showed that ACEI admin-
istration that is started 0–36 h from symptom onset is also
beneficial for acute myocardial infarction (1). Importantly,
however, two of the included trials, the Cooperative New
Scandinavian Enalapril Survival Study II (40) and the third
subanalysis of Gruppo Italiano per lo Studio della Streptochi-
nasi nell’Infarto Miocardico [Italian Group for the Study of
Streptokinase in Myocardial Infarction (3)] queried the bene-
ficial effect of ACEI in the very early phase of acute myocar-
dial infarction.
Circulating catecholamine levels increase beyond a physio-
logical level during heart failure (12). An excess amount of
catecholamines exacerbates cardiac dysfunction (6, 13, 36).
Consequently, the vicious circle of activation of the -adren-
ergic system and the RAS plays a crucial role in exacerbation
of heart failure (38).
We introduced an acute cardiac dysfunction model induced
by infusion of a large amount of isoproterenol (Iso) in dogs.
Excess stimulation of -adrenergic receptors causes desensiti-
zation and downregulation of the -adrenergic signal transduc-
tion system (9, 10, 28). We investigated whether ACEI and
ARB equally prevent Iso-induced acute cardiac dysfunction
and -adrenergic desensitization in this model.
MATERIALS AND METHODS
Experimental Animals and Preparation
This investigation conforms to the Guide for the Care and Use of
Laboratory Animals published by the National Institutes of Health
(NIH Pub. No. 85-23, revised 1996) and the guidelines of the
Committee on Laboratory Animals of the Asahikawa Medical Col-
lege.
Twenty-two adult mongrel dogs of either sex were anesthetized
with pentobarbital sodium (30 mg/kg iv) and ventilated with oxygen-
enriched air using a volume-limited ventilator (model 613; Harvard
Apparatus; South Natick, MA). Arterial blood gas values were kept
within a physiological range by adjusting the ventilator. An incision
was made in the fifth left intercostal space. An aortic occluder made
of polyethylene tubing was placed around the descending aorta. A
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bipolar pacing electrode was positioned on the left atrial appendage
through a small pericardial incision and connected to a cardiac
stimulator (SEC-2102; Nihon Kohden; Tokyo, Japan). A polyethylene
catheter was inserted through the left carotid artery into the ascending
aorta to withdraw blood samples and was connected to strain-gauge
manometers (TP-101T; Nihon Kohden) to monitor arterial pressure.
The catheters were inserted through the bilateral femoral veins to
infuse drugs. LV pressure (LVP), LV end-diastolic pressure
(LVEDP), rate of change of LVP (LV dP/dt), and the time constant of
isovolumic relaxation of the left ventricle () were measured by a
catheter-tipped transducer (PC-350; Millar; Houston, TX) inserted
from the right carotid artery into the left ventricle. A 5-MHz single-
plane transducer for transesophageal echocardiography (SSD-830;
Aloka; Tokyo) was placed just behind the LV to monitor the changes
in LV dimension (Fig. 1).
Experimental Protocol
Dogs were randomly assigned to three groups. One group received
only a 1 g kg1 min1 Iso infusion (control group, n  5 dogs).
The second group received infusion of 0.05 mg/kg olmesartan
(Sankyo; Tokyo, Japan) 15 min before Iso infusion was started (ARB
group, n  6 dogs). The third group received infusion of 0.05 mg/kg
temocaprilat (Sankyo) 15 min before Iso infusion was started (ACEI
group, n  6 dogs). In the preliminary study, we tested the infusion
of 0.01, 0.02, 0.05, 0.08, and 0.1 mg/kg temocaprilat and olmesartan
in dogs. The pressor effects of 1.0 g/kg angiotensin I (ANG I) and
0.5 g/kg ANG II were dose dependently suppressed by temocaprilat
and olmesartan, respectively. However, 0.08 mg/kg temocaprilat or
olmesartan showed slight but significant depressor effects. Accord-
ingly, we determined that for both agents, 0.05 mg/kg was the
maximum dose that did not significantly affect systemic blood pres-
sure but sufficiently suppressed the equivalent pressor effects of ANG
I and ANG II by temocaprilat and olmesartan, respectively: the
pressor effects of 1.0 g/kg ANG I were significantly suppressed by
0.05 mg/kg temocaprilat (from 56.5  3.3 to 11.5  2.3 mmHg, n 
4 dogs; P  0.01), and the pressor effects of 0.5 g/kg ANG II were
suppressed by 0.05 mg/kg olmesartan (from 57.0  2.9 to 9.5  0.6
mmHg, n  4 dogs; P  0.01). There were no significant differences
in the antipressor effects of temocaprilat (79.9  3.4%) and olme-
sartan (83.1  1.9%). The changes in hemodynamics were com-
pared under conditions of constantly maintained aortic pressure and
heart rate to the baseline levels, which were finely and hourly
readjusted using an aortic occluder and atrial pacing (Fig. 1). The
responses to test applications of low doses of Iso (0.025, 0.05, 0.1, and
0.2 g kg1 min1) were compared before and 3 h after the contin-
uous infusion of the Iso loading with 15-min cessation of the loading
infusion under conditions in which the pretest aortic pressure and
heart rate were adjusted to baseline levels.
Additionally, the results from the ACEI group led us to test a fourth
group, which received a 0.05 g kg1 min1 HOE-140 infusion in
addition to ACEI (ACEI 	 HOE-140 group, n  5 dogs). We
determined the dose of HOE-140 that completely abolished the
depressor effects of a 2.0 g/kg bradykinin injection (which caused an
approximately 50-mmHg reduction in systemic blood pressure) and
did not affect systemic blood pressure itself.
Blood Sampling
Aortic blood samples were periodically collected from left carotid
artery. Aortic blood gas values were checked with a blood gas
analyzer (Bayer 850; Sudbury, UK). Plasma rennin activity (PRA)
and serum aldosterone and ANG II levels were measured via radio-
immunoassay, plasma atrial natriuretic peptide (ANP) values were
obtained by immunoradiometric assay, and lipid peroxide (LPO)
quantities were identified via a hemoglobin-methylene blue method.
Data Analysis and Statistics
All hemodynamic data were monitored on a direct-writing oscillo-
graph (polygraph system RM 6200; Nihon Kohden) and were contin-
uously digitized and recorded on a personal computer throughout the
study using a physiological data-acquisition system (ADInstrument;
Taustralia; NSW, Australia). We derived  values from a digitized LV
pressure wave against time. LV end-diastolic dimension (LVEDd) and
LV end-systolic dimension (LVESd) were measured by M-mode
transesophageal echocardiography. LV percent fractional shortening
(%FS) was calculated as [(LVEDd  LVESd)/LVEDd] 
 100. LV
Fig. 1. Schematic illustration of instrumentation used
in assessing hemodynamics and left ventricular (LV)
function. A 5-MHz transducer for transesophageal
echocardiography (TEE) was placed just behind the
LV to monitor changes in LV dimension.
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ejection fraction (LVEF) was calculated as [(LVEDd3  LVESd3)/
LVEDd3] 
100 (19). The data were stored and analyzed using a
personal computer. All values are expressed as means  SE. Differ-
ences between baseline measurements and subsequent values were
analyzed using repeated-measures ANOVA. When significant differ-
ences were detected, individual mean values were compared using
Fisher’s protected least-significant difference test. P  0.05 was
considered to indicate statistical significance.
RESULTS
Changes in LV Function by Iso Infusion in Each Group
There were no significant differences in baseline hemody-
namic parameters among the four groups (Table 1). Heart rate
and mean aortic pressure values were maintained almost con-
stant by applying atrial pacing and aortic banding throughout
the protocol. Consequently, there were no significant differ-
ences in heart rate and mean aortic pressure among the four
groups after 3 h (Table 1). After 3 h of Iso infusion, the
maximum LV dP/dt (LV dP/dtmax) was maintained and was
still significantly higher in the ARB group than in the control
and ACEI groups (P  0.05; Table 1). The significant differ-
ence with ACEI tended to be diminished by cotreatment with
HOE-140.
In the control group, there were significant decreases in
LVEF (22  3%) and %FS (13  2%) values at 3 h after
Iso infusion compared with the baseline values (P  0.01; Fig.
2; Table 1). These changes in LV systolic function were
diminished in the ARB group in LVEF (6  2%) and %FS
(4  2%) compared with the control group (P  0.01). The
changes tended to diminish (but not significantly) in the ACEI
group in LVEF (15  2%) and %FS (9  1%) compared
with the control group. In contrast, these changes were signif-
icantly suppressed in the ACEI 	 HOE-140 group in LVEF
(8  1%) and %FS (6  1%; P  0.01 vs. control group;
Fig. 2 and Table 1).
LVEDP values were elevated significantly in all groups
except ARB at 3 h after Iso infusion (Fig. 3 and Table 1). The
elevation of LVEDP was significantly lower in the ARB (1.3
0.3 mmHg) compared with the control (5.6  1.0 mmHg) and
ACEI (4.7  0.7 mmHg) groups (P  0.01). It was relatively
but significantly lower in the ACEI 	 HOE-140 group (3.2 
1.0 mmHg) compared with the control group (P  0.05). The
Table 1. Hemodynamic parameters
Parameter
Treatment Group
Controla ARBb ACEIb
ACEI 	
HOE 
140a
Heart rate, beats/min
Pretreatment 1407 1427 1478 1406
Baseline 1389 1396 1437 1385
After 3 h 1389 1396 1437 1385
Mean aortic pressure,
mmHg
Pretreatment 11913 1216 1229 12111
Baseline 11811 1194 1187 11710
After 3 h 1055 1046 1069 1066
Maximum LV dP/dt,
mmHg/s
Pretreatment 2,42493 2,42773 2,41793 2,42479
Baseline 2,41687 2,40669 2,41181 2,40059
After 3 h 1,81999c 2,128154d 1,83771c 1,94960e
LV ejection fraction, %
Pretreatment 673 674 663 672
Baseline 674 674 662 671
After 3 h 453c 612f 511c 591c,f
LV fractional shortening,
%
Pretreatment 312 313 302 312
Baseline 313 313 302 311
After 3 h 182c 271f 211c 261e,f
LV end-diastolic pressure,
mmHg
Pretreatment 3.40.6 3.30.6 3.20.7 3.40.6
Baseline 3.40.7 3.20.6 3.20.8 3.40.4
After 3 h 9.01.5c 4.50.8f 7.80.9c 6.61.2e
, ms
Pretreatment 322 331 332 332
Baseline 331 331 322 333
After 3 h 413e 375 404 384
Values are means  SE; an  5; bn  6 dogs. Treatment infusions: control,
1 gkg1min1 isoproterenol (Iso); ARB (ANG II type I receptor blocker),
Iso 	 0.05 mg/kg olmesartan; ACEI (ANG II-converting enzyme inhibitor),
Iso 	 0.05 mg/kg temocaprilart; and ACEI 	 HOE-140, ACEI 	 0.05
gkg1min1 HOE-140. Each group (except control) received treatment
agent 15 min before Iso infusion. LV dP/dt, rate of change of LV (left
ventricular) pressure; , diastolic function. cP  0.01 vs. baseline; dP  0.05
vs. control; eP  0.05 vs. baseline; fP  0.01 vs. control.
Fig. 2. Changes in LV ejection fraction (LVEF, left)
and LV fractional shortening (%FS, right) 3 h after
isoproterenol (Iso) infusion. Both indexes were signifi-
cantly decreased in control animals. These changes
were suppressed significantly by angiotensin II type 1
receptor blocker (ARB), partially by angiotensin-con-
verting enzyme inhibitor (ACEI), and again signifi-
cantly by ACEI with HOE-140. Data are means  SE.
**P  0.01 vs. baseline; ††P  0.01 vs. control.
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prolongation of  was observed in the control group (9.2  3.2
ms; P  0.05); however, it was not evident in the ARB, ACEI,
and ACEI 	 HOE-140 groups (Fig. 3 and Table 1).
Changes in Dose Responses to Test Applications of Iso
Baseline responses. LV dP/dtmax was dose dependently
increased by test application of Iso in all groups. However, the
response in the ACEI group was significantly attenuated com-
pared with the control group (P  0.05) and was totally
restored by cotreatment with HOE-140. There were no signif-
icant differences between the control and ARB groups (Fig. 4).
Responses 3 h after Iso infusion. The responses of LV
dP/dtmax to test applications of Iso, which were assessed after
matching the heart rate and afterload to pretreatment levels in
all groups, were significantly attenuated in the control and
ACEI groups at 3 h after Iso infusion compared with the
baseline responses. The attenuation in responses was not abol-
ished in the ACEI 	 HOE-140 group but was almost com-
pletely abolished in the ARB group (Fig. 5).
PRA, Serum ANP, ANG II, and Aldosterone Levels
Baseline values of PRA, ANP, ANG II, and aldosterone
were not significantly different. PRA levels increased signifi-
cantly after Iso infusion in the control (14.4  4.1 to 32.9 
4.8 ng ml1 h1; P  0.01) and ACEI (14.9  3.2 to 33.8 
2.3 ng ml1 h1; P  0.01; Fig. 6) groups. In contrast, the
increases in PRA were not significant in the ARB group
(15.1  2.6 to 18.8  3.6 ng ml1 h1) and were significant
but relatively attenuated in the ACEI 	 HOE-140 group
(16.5 3.0 to 26.9 2.0 ng ml1 h1; P 0.05). ANP levels
were significantly higher after Iso infusion in the control
(11.2 2.1 to 45.1 10.1 pg/ml; P 0.01) and ACEI (13.0
2.5 to 44.9  6.5 pg/ml; P  0.01) groups. The increases in
ANP levels were not significant in the ARB group (12.1  2.6
to 22.1  8.9 pg/ml) and were significant but relatively
attenuated in the ACEI 	 HOE-140 group (10.8  2.3 to
38.0  6.1 pg/ml; P  0.01). Peak values for both PRA and
ANP were significantly lower in the ARB than the control and
ACEI groups, respectively (P  0.05; Fig. 6).
Serum ANG II levels were significantly higher after Iso
infusion in all groups and particularly in the ARB group
(control, 3,354  1,183; ARB, 5,410  1,788; ACEI, 723 
220; and ACEI 	 HOE-140, 936  478 pg/ml; P  0.05 vs.
baseline, respectively). Serum aldosterone levels were signifi-
cantly decreased after Iso infusion only in the ARB group
(176.5  23.1 to 107.5  17.5 pg/ml; P  0.01). The nadir of
serum aldosterone levels was significantly lower in the ARB
compared with the control group (107.5  17.5 vs. 204.2 
21.4 pg/ml; P  0.05).
Serum LPO Levels
The baseline levels for serum LPOs were not significantly
different among all groups. The LPO levels were significantly
higher after Iso infusion only in the control group (1.3 0.1 to
3.2  0.4 nmol/ml; P  0.01). The peak value for LPO levels
Fig. 3. Changes in LV end-diastolic pressure (LVEDP, left)
and time constant of isovolumic relaxation of the left ventricle
(, right) 3 h after Iso infusion. LVEDP values were signif-
icantly increased in control and ACEI groups. These changes
were attenuated significantly in ACEI 	 HOE-140 group and
more markedly in ARB group. In control group,  was
significantly prolonged 3 h after Iso infusion. *P  0.05; **P
 0.01 vs. baseline; †P  0.05; ††P  0.01 vs. control.
Fig. 4. Dose responses of LV dP/dt to test Iso application at baseline. LV dP/dt
increased dose dependently in all groups; however, the response was signifi-
cantly attenuated in ACEI compared with control groups (*P  0.05; **P 
0.01, respectively). These differences were completely abolished in the
ACEI 	 HOE-140 group.
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was significantly lower in the ARB compared to the control
group (1.8  0.4 vs. 3.2  0.4 nmol/ml; P  0.01; Fig. 6).
DISCUSSION
We introduced an experimental model of acute LV dysfunc-
tion induced by infusion of a large Iso dose in dogs. The
-adrenergic stimulation activates the RAS, which causes
myocardial damage mainly through AT1 receptors (25), and
ANG II stimulates release of norepinephrine from the adrenal
medulla and sympathetic nervous terminals (8, 44). The vi-
cious circle of activation of the -adrenergic system and the
RAS aggravates heart failure. Thus the breaking of this circle
is a potential strategy for the treatment of heart failure.
In the present study, we found a significant difference
between the effects of ACEI and ARB on acute cardiac
dysfunction. ARB almost totally but ACEI only partially pre-
vented acute cardiac dysfunction induced by a large-dose Iso
infusion. More interestingly, ACEI significantly attenuated
responses to Iso administration.
The cardioprotective effects of ACEI in heart failure have
been mainly attributable to inhibition of bradykinin degrada-
tion in addition to inhibition of ACE (29, 30). Bradykinin
facilitates the generation of NO and prostacyclin, both of
which are also known to be beneficial in the treatment of
myocardial ischemia and heart failure. However, this concept
may not be applicable to the acute phase of cardiac dysfunction
that is induced by excess -adrenergic stimulation. In the case
in which we applied ACEI with HOE-140 (a bradykinin B2
receptor antagonist), the effect was partially improved but it
compared significantly with the effect of ACEI alone. The dose
of HOE-140 that we used in the present study was determined
to completely abolish the depressor effects of a 2.0 g/kg
bradykinin injection (an approximately 50-mmHg decrease
in systemic blood pressure) while not affecting systemic blood
pressure. Thus the inferior effect of ACEI compared with ARB
is attributable at least in part to the bradykinin pathway.
It is noteworthy that ACEI markedly suppressed the positive
inotropic response to Iso at baseline, which was not observed
in the ARB group and was completely restored by coadminis-
tration of HOE-140. NO released by bradykinin is known to
inhibit myocardial contractility in vivo as well as in vitro and
particularly in pathological conditions (7, 18, 20, 42, 43).
Importantly, the positive inotropic response to -adrenergic
stimulation is known to be suppressed by NO (18, 42, 43). We
have previously demonstrated that LV dysfunction is indirectly
aggravated even with inhaled NO in heart failure (32).
More directly, bradykinin itself has been reported to inhibit
myocardial contraction independent of NO or prostacyclin (5,
17, 37). One plausible mechanism for the negative inotropic
action of bradykinin is based on cytochrome P-450 metabo-
lites, which are a major candidate for an endothelial-derived
hyperpolarizing factor (11, 21). Rastaldo et al. (37) demon-
strated that the negative inotropic response to bradykinin was
abolished by cytochrome P-450 inhibitors and was not affected
by NO and cyclooxygenase inhibitors in isolated perfused rat
heart. The positive inotropic response to Iso at baseline was
Fig. 5. Dose responses of LV dP/dt to test Iso
applications were compared at baseline and
3 h after excess Iso infusion. Responses were
significantly attenuated 3 h after Iso infusion
in the control group (top left) as well as in the
ACEI group (bottom left). Responses were
not restored in ACEI 	 HOE-140 group 3 h
after excess Iso infusion (bottom right). In
contrast, responses were almost totally pre-
served in ARB group (top right). *P  0.05;
**P  0.01 vs. baseline.
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significantly suppressed by ACEI through the bradykinin path-
way in the present study. However, this inotropic response was
no longer restored 3 h after infusion of a large dose of Iso. This
was probably because the cardiac dysfunction induced by
excess -adrenergic stimulation for 3 h was too serious to be
affected by HOE-140.
We found an intriguing coincidence between our results and
those of the two major clinical trials that queried the beneficial
effects of ACEI in the acute phase of heart failure. CONSEN-
SUS II (40) and the subanalysis of GISSI-3 (3) both demon-
strated that ACEI therapies initiated early after the onset of
acute myocardial infarction failed to improve the survival rate.
Their results were ascribed to the harmful hypotensive reaction
of ACEI and inhibition of the myocardial healing process
mediated by ANG II (3, 40). In addition to these, the negative
inotropic action of bradykinin, which we found in the present
study (conducted with constant afterload and heart rate), is
another potentially deleterious factor in the treatment of the
acute phase of cardiac dysfunction with ACEI. In contrast,
there are few clinical data on ARB. The Optimal Trial in
Myocardial Infarction with ANG II Antagonist Losartan (14)
and the Valsartan Acute Myocardial Infarction Trial (33)
demonstrated that ARB is as effective as ACEI in acute
myocardial infarction that is treated 12 h from onset. There
are no data available regarding ARB and the very early phase
of acute myocardial infarction. In clinical settings, it may be
possible that the clinical course of the very early phase of acute
cardiac dysfunction differs depending on which drug, ACEI or
ARB, that patients have taken as antihypertensive agents be-
fore the onset of the event. This concept has never been studied
in a major clinical trial.
Numerous experimental studies of myocardial infarction and
heart failure conducted in rats suggest that the cardioprotective
effects of ARB are equivalent or inferior to those of ACEI (23,
41). ANG II is exclusively produced by ACE in rats (4). In
contrast, it is also produced through alternative pathways such
as via chymase in humans and dogs (2, 4); for this reason, we
used dogs in the present study. Theoretically, the effects of
ANG II might be completely suppressed by ARB, whereas the
effects are not suppressed by ACEI in humans and dogs. We
believe this could be an important explanation for the differ-
ences in effects between ARB and ACEI in the present study.
The serum LPO levels were increased by excess Iso admin-
istration and were prevented by ARB and ACEI. Oxidative
stress is known to be enhanced and to cause deterioration of
cardiac function in heart failure (22, 26, 27). Reduction of
oxidative stress is one of the potential mechanisms of cardio-
protective action for ARB and ACEI in this model. Excess Iso
infusion activated the RAS and enhanced ANP release. The
increase in serum ANP levels was significantly suppressed
only by ARB. These results suggest that ARB potently sup-
pressed the RAS and provided greater cardioprotective effects
than ACEI in this acute cardiac dysfunction model.
Study Limitations
We examined the acute effects of ARB and ACEI in this
study. The deterioration of the animal’s condition is extremely
serious after excess Iso infusion, and therefore we were unable
to continue experiments with Iso infusion longer than the
studied periods. It is possible that the chronic effects of ARB
and ACEI could be different from the acute effects.
Fig. 6. Plasma rennin activity (PRA; top left), atrial natri-
uretic peptide (ANP; top right), and lipid peroxide (LPO;
bottom) levels at baseline and 3 h after Iso infusions. PRA
and ANP were significantly increased in control and ACEI
groups. These changes were attenuated slightly in ACEI 	
HOE-140 group and were significantly abolished in ARB
group. LPO levels were significantly increased in control
group; however, the changes were attenuated in all other
groups particularly in ARB compared with the control
group. *P  0.05; **P  0.01 vs. baseline; †P  0.05;
††P  0.01 vs. control.
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We selected and examined the maximum doses of ACEI and
ARB that did not significantly affect systemic blood pressure
but did sufficiently suppress pressor effects of ANG I and ANG
II, for ACEI and ARB, respectively. We then compared those
maximum doses of ARB and ACEI in the present study. It is
possible that different doses of agents, and particularly differ-
ent doses of ACEI, would modify the results. However, even at
baseline, ACEI at the dose used markedly suppressed the
responses to the test application of Iso, which was totally
restored by HOE-140; this clearly suggests that bradykinin was
the major factor responsible for the attenuated responses to Iso
by ACEI.
The experimental model of cardiac dysfunction used in the
present study does not fully represent the acute phase of
myocardial infarction. Therefore, additional study is required
to confirm the clinical significance of the difference between
ARB and ACEI that was observed in this study, particularly in
the very early phase of acute myocardial infarction.
In conclusion, LV dysfunction and -adrenergic desensiti-
zation induced by excess -adrenergic stimulation were pre-
vented almost totally by ARB and partially by ACEI. Activat-
ing bradykinin pathways by ACEI administration may not be
beneficial in the very early phase of heart failure. Additional
investigation is required to clarify the differences between
ACEI and ARB in the very early phase of acute heart failure,
which is accompanied with a storm of sympathetic activation.
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